Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022
10/18/2022 - 08:30 AM
CRANFORD, N.J. Oct. 18, 2022 Leonard Mazur will be presenting at the ThinkEquity Conference on October 26, 2022 .
Conference Details:
Date:
October 26, 2022
Time:
1:00PM ET
Location:
The Mandarin Oriental Hotel in New York, New York
Live presentation:
Viewers must register for the conference to view the live presentation.
Webcast replay:
Available for the following 90 days on the Company's Investors website .
One-on-one Meetings:
Investors may request meetings online upon registration.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company's diversified pipeline includes two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), for which a BLA has been submitted. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). In the first half of 2022, Citius initiated a Phase 2b trial for Halo-Lido, a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com .
Investor Contact:
Ilanit Allen ir@citiuspharma.com
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-thinkequity-conference-on-october-26-2022-301651872.html
SOURCE Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals Inc
CTXR Rankings
#3945 Ranked by Stock Gains
CTXR Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
US
City
Cranford
About CTXR
citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.
